{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:14:13Z","timestamp":1792091653766,"version":"4.4.0"},"reference-count":30,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objectives: The present study investigated the correlation between \u03b1 B-crystallin (CRYAB, HSPB5) and p53 expression in ovarian cancer and further analyzed the relationship between their expression and clinicopathology and the prognostic value of their co-expression in ovarian cancer. Methods: CRYAB and p53 expression was assessed using immunohistochemistry on ovarian cancer tumor tissues from 103 cases and validated in an independent group of 103 ovarian cancer patients. Results: High CRYAB and p53 expression rates in ovarian cancer tissues were 61.17% (63\/103) and 57.28% (59\/103), respectively, and their expression was positively correlated (r = 0.525, P=0.000). High CRYAB expression was significantly correlated with tumor size (P=0.028), lymph node metastasis (P=0.000), distant metastasis (P=0.005), tumor node metastasis (TNM) stage (P=0.002), and survival (P=0.000), while high p53 expression was significantly correlated with tumor size (P=0.006), pathological grade (P=0.023), lymph node metastasis (P=0.001), and survival (P=0.000). Further studies found that the high CRYAB and p53 co-expression was also significantly correlated with pathological grade (P=0.024), lymph node metastasis (P=0.000), Distant metastasis (P=0.015), TNM stage (P=0.013), and survival (P=0.000). High expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were significantly correlated with poor disease-free survival (DFS) and overall survival (OS), respectively (P&amp;lt;0.05). Patients with high CRYAB and p53 co-expression had the worst prognoses among the groups. In addition, multivariate Cox regression models showed that high expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were independent prognostic factors for DFS and OS (P&amp;lt;0.05). Moreover, the positive correlation and prognostic value of CRYAB and p53 expression were verified in another independent dataset. Conclusions: We demonstrated that patients with high CRYAB and p53 co-expression in ovarian cancer have significantly increased risks of recurrence, metastasis, and death compared with other patients. Therefore, more frequent follow-up of patients with high CRYAB and p53 co-expression is required. Our results also suggest that combination therapy with CRYAB inhibitors and p53 blockers may benefit future treatment of ovarian cancer patients with high co-expression of CRYAB and p53.<\/jats:p>","DOI":"10.1042\/bsr20182407","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:55:11Z","timestamp":1559303711000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High \u03b1 B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer"],"prefix":"10.1042","volume":"39","author":[{"given":"Lin","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Pukou District Central Hospital, Pukou Branch of Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, 166 Shanghe street, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 ZhongShan Road, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pukou District Central Hospital, Pukou Branch of Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, 166 Shanghe street, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-3546","authenticated-orcid":false,"given":"Qian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pukou District Central Hospital, Pukou Branch of Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, 166 Shanghe street, Nanjing, Jiangsu, China"},{"name":"Department of Pathology, The Second Chinese Medicine Hospital of Jiangsu Province, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pukou District Central Hospital, Pukou Branch of Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, 166 Shanghe street, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"2021111619431239800_B1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2021111619431239800_B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"2021111619431239800_B3","first-page":"2451","article-title":"International patterns and trends in ovarian cancer incidence, overall and by histologic subtype","volume":"140","author":"Coburn","year":"2017","journal-title":"Health Sci. Res."},{"key":"2021111619431239800_B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021111619431239800_B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ygyno.2018.08.005","article-title":"Surgical prevention strategies in ovarian cancer","volume":"151","author":"Mallen","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"2021111619431239800_B6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature05935","article-title":"Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination","volume":"448","author":"Ousman","year":"2007","journal-title":"Nature"},{"key":"2021111619431239800_B7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2559.2011.03882.x","article-title":"Increased alpha-B-crystallin expression in mammary metaplastic carcinomas","volume":"59","author":"Chan","year":"2011","journal-title":"Histopathology"},{"key":"2021111619431239800_B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-13-1255","article-title":"alphaB-crystallin: a novel regulator of breast cancer metastasis to the brain","volume":"20","author":"Malin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2021111619431239800_B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1756-9966-31-101","article-title":"Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma","volume":"31","author":"Mao","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2021111619431239800_B10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.2353\/ajpath.2010.090063","article-title":"alphaB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells","volume":"177","author":"Goplen","year":"2010","journal-title":"Am. J. Pathol."},{"key":"2021111619431239800_B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-014-0142-1","article-title":"Elevated expression of CRYAB predicts unfavorable prognosis in non-small cell lung cancer","volume":"31","author":"Qin","year":"2014","journal-title":"Med. Oncol."},{"key":"2021111619431239800_B12","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1111\/jcmm.13602","article-title":"Alpha B-crystallin promotes the invasion and metastasis of gastric cancer via NF-kappaB-induced epithelial-mesenchymal transition","volume":"22","author":"Chen","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"2021111619431239800_B13","first-page":"6056","article-title":"Alpha B-crystallin correlates with poor survival in colorectal cancer","volume":"7","author":"Shi","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"2021111619431239800_B14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbrc.2017.05.070","article-title":"Alpha B-crystallin promotes the invasion and metastasis of colorectal cancer via epithelial-mesenchymal transition","volume":"489","author":"Shi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619431239800_B15","doi-asserted-by":"publisher","first-page":"pii: E442","DOI":"10.3390\/ijms18020442","article-title":"Essential roles of E3 ubiquitin ligases in p53 regulation","volume":"18","author":"Sane","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"2021111619431239800_B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13287-017-0498-1","article-title":"p53 switches off pluripotency on differentiation","volume":"8","author":"Lin","year":"2017","journal-title":"Stem Cell. Res. Ther."},{"key":"2021111619431239800_B17","first-page":"83","article-title":"Transcriptional inhibitors, p53 and apoptoss","volume":"1786","author":"Gartel","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111619431239800_B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2013.12.025","article-title":"Tumor suppressor p53 and its mutants in cancer metabolism","volume":"356","author":"Liu","year":"2015","journal-title":"Cancer Lett."},{"key":"2021111619431239800_B19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"2021111619431239800_B20","doi-asserted-by":"publisher","first-page":"pii: a026252","DOI":"10.1101\/cshperspect.a026252","article-title":"TP53 mutations in breast and ovarian cancer","volume":"7","author":"Silwal-Pandit","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2021111619431239800_B21","doi-asserted-by":"publisher","first-page":"19257","DOI":"10.3390\/ijms140919257","article-title":"The consequence of oncomorphic TP53 mutations in ovarian cancer","volume":"14","author":"Brachova","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"2021111619431239800_B22","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1158\/1078-0432.CCR-03-0751","article-title":"Cyclin D1, p53, and p21Waf1\/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer","volume":"10","author":"Bali","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2021111619431239800_B23","first-page":"5134","article-title":"Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis","volume":"22","author":"Liang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2021111619431239800_B24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bbrc.2006.12.152","article-title":"Small heat shock protein alphaB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis","volume":"354","author":"Liu","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619431239800_B25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bbagrm.2014.05.017","article-title":"As a novel p53 direct target, bidirectional gene HspB2\/alphaB-crystallin regulates the ROS level and Warburg effect","volume":"1839","author":"Liu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111619431239800_B26","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/PAI.0000000000000370","article-title":"IHC optical density score: a new practical method for quantitative immunohistochemistry imageanalysis","volume":"25","author":"Seyed Jafari","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"2021111619431239800_B27","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1016\/j.febslet.2007.04.033","article-title":"Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets","volume":"581","author":"Arrigo","year":"2007","journal-title":"FEBS Lett."},{"key":"2021111619431239800_B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.012","article-title":"alphaB-crystallin: portrait of a malignant chaperone as a cancer therapeutic target","volume":"160","author":"Malin","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"2021111619431239800_B29","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1002\/ijc.27975","article-title":"High expression of crystallin alphaB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells","volume":"132","author":"Volkmann","year":"2013","journal-title":"Int. J. Cancer"},{"key":"2021111619431239800_B30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/jcb.22151","article-title":"Heat shock factor 1 deficiency via its downstream target gene alphaB-crystallin (Hspb5) impairs p53 degradation","volume":"107","author":"Jin","year":"2009","journal-title":"J. Cell. Biochem."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20182407\/846359\/bsr-2018-2407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20182407\/846359\/bsr-2018-2407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T15:29:23Z","timestamp":1637076563000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/6\/BSR20182407\/219305\/High-B-crystallin-and-p53-co-expression-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20182407","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,6]]},"article-number":"BSR20182407"}}